Pulmatrix Inc (PULM) - Net Assets
Based on the latest financial reports, Pulmatrix Inc (PULM) has net assets worth $3.59 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.50 Million) and total liabilities ($905.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Pulmatrix Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.59 Million |
| % of Total Assets | 79.87% |
| Annual Growth Rate | 40.23% |
| 5-Year Change | -91.97% |
| 10-Year Change | -56.51% |
| Growth Volatility | 8265.24 |
Pulmatrix Inc - Net Assets Trend (2012–2025)
This chart illustrates how Pulmatrix Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Pulmatrix Inc.
Annual Net Assets for Pulmatrix Inc (2012–2025)
The table below shows the annual net assets of Pulmatrix Inc from 2012 to 2025. Also explore Pulmatrix Inc net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.81 Million | -57.42% |
| 2024-12-31 | $8.95 Million | -50.28% |
| 2023-12-31 | $18.00 Million | -42.16% |
| 2022-12-31 | $31.11 Million | -34.44% |
| 2021-12-31 | $47.45 Million | +105.06% |
| 2020-12-31 | $23.14 Million | +109.99% |
| 2019-12-31 | $11.02 Million | -6.97% |
| 2018-12-31 | $11.84 Million | +16.84% |
| 2017-12-31 | $10.14 Million | +15.71% |
| 2016-12-31 | $8.76 Million | -73.13% |
| 2015-12-31 | $32.61 Million | +122.89% |
| 2014-12-31 | $14.63 Million | 0.00% |
| 2013-12-31 | $14.63 Million | +31025.53% |
| 2012-12-31 | $47.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pulmatrix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30229000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $306.13 Million | 8034.86% |
| Total Equity | $3.81 Million | 100.00% |
Pulmatrix Inc Competitors by Market Cap
The table below lists competitors of Pulmatrix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hansa Investment Company Ltd
LSE:HANA
|
$5.23 Million |
|
Combigene AB
ST:COMBI
|
$5.24 Million |
|
VIA OPTRONICS AG SP.ADS/1
F:5UU1
|
$5.24 Million |
|
Ace Digital AS
OL:ACED
|
$5.24 Million |
|
Exact Therapeutics AS
OL:EXTX
|
$5.23 Million |
|
Qualitech Public Company Limited
BK:QLT
|
$5.22 Million |
|
Wickes Group PLC
LSE:WIX
|
$5.22 Million |
|
FBS Global Limited Ordinary Shares
NASDAQ:FBGL
|
$5.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pulmatrix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,947,000 to 3,810,000, a change of -5,137,000 (-57.4%).
- Net loss of 5,162,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.16 Million | -135.49% |
| Other Changes | $25.00K | +0.66% |
| Total Change | $- | -57.42% |
Book Value vs Market Value Analysis
This analysis compares Pulmatrix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.37x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-7.00 | $1.43 | x |
| 2012-12-31 | $11.75 | $1.43 | x |
| 2013-12-31 | $3592.58 | $1.43 | x |
| 2014-12-31 | $3592.58 | $1.43 | x |
| 2015-12-31 | $806.10 | $1.43 | x |
| 2016-12-31 | $118.27 | $1.43 | x |
| 2017-12-31 | $104.66 | $1.43 | x |
| 2018-12-31 | $57.41 | $1.43 | x |
| 2019-12-31 | $13.17 | $1.43 | x |
| 2020-12-31 | $16.09 | $1.43 | x |
| 2021-12-31 | $17.52 | $1.43 | x |
| 2022-12-31 | $9.02 | $1.43 | x |
| 2023-12-31 | $4.93 | $1.43 | x |
| 2024-12-31 | $2.45 | $1.43 | x |
| 2025-12-31 | $1.04 | $1.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pulmatrix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -135.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-135.49%) is above the historical average (-182.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-27.20K |
| 2012 | -1112.77% | -80.09% | 4.41x | 3.15x | $-527.70K |
| 2013 | -21.31% | -885.80% | 0.02x | 1.06x | $-4.58 Million |
| 2014 | -165.04% | -6859.09% | 0.02x | 1.06x | $-25.61 Million |
| 2015 | -80.25% | -2178.77% | 0.03x | 1.38x | $-29.43 Million |
| 2016 | -317.81% | -3334.49% | 0.05x | 1.90x | $-28.72 Million |
| 2017 | -178.12% | -5389.85% | 0.02x | 1.58x | $-19.07 Million |
| 2018 | -173.62% | -13439.87% | 0.01x | 1.24x | $-21.75 Million |
| 2019 | -186.91% | -260.38% | 0.22x | 3.28x | $-21.70 Million |
| 2020 | -83.44% | -152.83% | 0.33x | 1.65x | $-21.62 Million |
| 2021 | -42.51% | -390.23% | 0.09x | 1.24x | $-24.92 Million |
| 2022 | -60.19% | -308.43% | 0.15x | 1.32x | $-21.84 Million |
| 2023 | -78.47% | -193.49% | 0.21x | 1.89x | $-15.92 Million |
| 2024 | -106.84% | -122.46% | 0.79x | 1.11x | $-10.45 Million |
| 2025 | -135.49% | 0.00% | 0.00x | 1.09x | $-5.54 Million |
Industry Comparison
This section compares Pulmatrix Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pulmatrix Inc (PULM) | $3.59 Million | 0.00% | 0.25x | $5.23 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Pulmatrix Inc
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.… Read more